Roche Q1 Report 2023

• As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3% at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%
• Pharmaceuticals Division sales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driver
• Diagnostics Division base business grows 4%, while divisional sales are 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022

Highlights in the first quarter:

• • US approval of Polivy (first-line treatment for an aggressive form of blood cancer)
  • EU approval of Hemlibra (moderate haemophilia A)
  • Positive phase III data for Vabysmo (retinal vein occlusion, a serious eye disease), Tecentriq plus Avastin (adjuvant therapy for certain forms of liver cancer) and crovalimab (paroxysmal nocturnal haemoglobinuria, a rare blood disease)
  • Positive four-year efficacy and safety data for Evrysdi (spinal muscular atrophy)
  • Launch of new assays to identify clinically relevant mutations in brain cancers